Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: 8R-70CAR T Cell Therapy in CD70+ Adult GBM
NCT05353530Phase 1Active, not recruiting
- Sponsor
- University of Florida
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 8R-70CAR T-cells in glioblastoma (GBM), sponsored by University of Florida. Primary endpoints: Safety of 8R-70CAR T-cell therapy and Feasibility of 8R-70CAR T-cell therapy at 10 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
8R-70CAR T-cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05353530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353530.